利维体痴呆症:临床诊断和管理的实用指南
Sarah Fullam1,2, Judith R Harrison3, Kirstie N Anderson4
1Tallaght Institute of Memory and Cognition, Tallaght University Hospital, Dublin, Ireland sfullam@tcd.ie.
Practical neurology
|October 5, 2025
概括
患有莱维体的痴呆症 (DLB) 经常被误诊,导致护理延迟. 本综述为神经病学家提供了实际指导,以改善早期DLB的识别和管理.
科学领域:
- 神经学 神经学
- 神经退行性疾病 神经退行性疾病
背景情况:
- 勒维体痴呆症 (DLB) 是老年人痴呆的一个重要原因.
- DLB经常被低诊断和误诊,导致诊断延迟与其他痴呆症相比.
研究的目的:
- 为神经科医生提供实用建议,以识别DLB的古典,前期和变体形式.
- 引导对DLB的诊断工具的适当使用.
- 在临床环境中提供DLB的实际管理策略.
主要方法:
- 这是一个复习文章.
- 它综合了关于DLB诊断和管理的当前知识.
- 专注于神经病学家的实际临床应用.
主要成果:
- 由于诊断不足和误诊,DLB诊断往往会延迟.
- 新兴疗法需要及时和准确的诊断.
- 实际的诊断和管理策略对于改善患者的治疗结果至关重要.
结论:
- 提高DLB亚型的识别是必不可少的.
- 适当地利用诊断模式可以帮助及时诊断.
- 专注的临床管理可以改善DLB患者的护理.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.2K
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.5K
相关概念视频
Dementia
517
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
517
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
Parkinson's Disease: Treatment
983
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
983
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
